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(57) ABSTRACT 
A non-invasive method for determining blood level of an 
analyte of interest, such as glucose, comprises: generating an 
excitation laser beam (e.g., at a wavelength of 700 to 900 
nanometers); focusing the excitation laser beam into the 
anterior chamber of an eye of the subject so that aqueous 
humor in the anterior chamber is illuminated; detecting 
(preferably confocally detecting) a Raman spectrum from 
the illuminated aqueous humor; and then determining the 
blood glucose level (or the level of another analyte of 
interest) for the subject from the Raman spectrum. 
Preferably, the detecting step is followed by the step of 
subtracting a confounding fluorescence spectrum from the 
Raman spectrum to produce a difference spectrum; and 
determining the blood level of the analyte of interest for the 
subject from that difference spectrum, preferably using 
linear or nonlinear multivariate analysis such as partial least 
squares analysis. Apparatus for carrying out the foregoing 
method is also disclosed. 
27 Claims, 8 Drawing Sheets 
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NON-INVASIVE GLUCOSE MONITOR 
This application claims the benefit of U.S. Provisional 
Application No. 601092,545, filed Jul. 13, 1998, the disclo- 
sure of which is incorporated by reference herein in its 
entirety. 
The invention described herein was made in the perfor- 
mance of work under a NASA contract, and is subject to the 
provisions of Public Law 96-517 (35 USC 202) in which the 
Contractor has elected to retain title. 
FIELD OF THE INVENTION 
The present invention concerns methods and apparatus for 
the non-invasive monitoring of blood glucose levels by 
spectrographic analysis of the aqueous humor in the anterior 
chamber of the eye. 
BACKGROUND OF THE INVENTION 
Non-invasive measurement of blood glucose by any 
method including optical spectroscopy techniques has 
remained an elusive target for at least two decades. Blood, 
tissue, and most excreted fluids contain numerous sub- 
stances which confound glucose spectral signatures. On the 
other hand, aqueous humor (AH) filling the anterior cham- 
ber of the eye (between the lens and cornea) contains 
relatively few molecules capable of interfering with the 
spectroscopic detection of glucose. These are primarily 
lactate, ascorbate, and urea. This fact, and its optically 
accessible location behind the cornea, make AH an attractive 
choice as a site on which to attempt non-invasive analysis of 
glucose. 
Pohjola (Acta Ophthalmologica Suppl. 88, 1-80 (1996)) 
showed that the ratio of aqueous glucose to plasma glucose 
in normal euglycemic individuals is related to age and 
ranges from 0.6 to 0.9. He further showed in seven humans 
with steady-state hyperglycemia that similar ratios applied. 
No data exists on the equilibration time of aqueous humor 
glucose with changes in plasma glucose in humans. 
Numerous investigators over the years have suggested 
that the ratio of aqueous glucose to plasma glucose in the 
normoglycemic rabbit ranges from 0.42 to 1.01 (S. Pohjola, 
supra; D. Reddy and V. Kinsey, Arch. Ophthalmol. 63, 
715-720 (1960); M. Reim et al., Ophthalmologica 154, 
39-50 (1967); W. March et al., Diabetes Care 5, 259 
(1982)). It is uncertain whether this variability is normal or 
could be attributed to differences in glucose measurement 
techniques, collection techniques, sample storage, and anes- 
thesia. The relationship of aqueous glucose to rising, or 
falling, plasma glucose has not been previously studied in 
rabbits. 
Cot6 has reviewed the relative strengths and weaknesses 
of optical glucose sensing techniques (J. Clin. Engineering 
22, 253 (1997)). Raman spectroscopy is potentially attrac- 
tive because it can distinguish glucose in water solutions 
containing various levels of other optically active metabo- 
lites (S. Wang et al.,Applied Optics 32, 925 (1993)). Raman 
spectroscopy measures the shift in the wavelength of inci- 
dent light as it is scattered by molecules. Any given mol- 
ecule causes a characteristic shift in the spectrum of scat- 
tered light, which is dependent upon its intermolecular and 
intramolecular bonds. This is in contradistinction to 
fluorescence, which is caused by changes in electron energy 
states, and does not shift relative to the wavelength of 
incident light. 
Wicksted et al, (Appl. Sectroscop. 49,987 (1995)) suggest 















aqueous humor samples, and Goetz, et a1 (ZEEE Tram. 
Biomed. Eng. 42, 728 (1995)), have demonstrated that 
higher than physiologic levels of glucose can be measured 
with Raman spectroscopy in water solutions. J. Lambert et 
al., (LEOS Newsletter 12, 19-22 (1998)) suggest that mea- 
surement of glucose at physiologic levels is possible in 
water solutions containing other analytes normally found in 
aqueous humor. When solutions containing fluorescent sub- 
stances are studied, however, the fluorescence signal can 
overwhelm the relatively weak Raman-shifted signal. This is 
a potential problem if Raman spectroscopy is applied to 
aqueous humor, which contains proteins that fluoresce. 
U.S. Pat. No. 5,243,983 to Tarr et al. suggest a non- 
invasive blood glucose measurement system using stimu- 
lated Raman spectroscopy. Stimulated Raman spectroscopy 
requires the use of both a pump and a probe laser beam. The 
probe laser beam is used to measure the stimulated Raman 
light at a single wavelength after transmission across the 
anterior chamber of the eye. This is undesirable, since an 
optical component contacting the eye is required to direct 
the beam across the anterior chamber. In addition, use of a 
single wavelength may limit the ability to measure glucose 
at physiologic levels within tissue containing many other 
Raman scattering chemicals. 
U.S. Pat. No. 5,433,197 to Stark suggests a non-invasive 
glucose measurement apparatus that employs broad band 
infrared light stimulation. 
U.S. Pat. No. 5,553,617 to Barkenhagen suggests a non- 
invasive method for measuring body chemistry from the eye 
of a subject by measuring a spectral response such as a 
Raman scattering response. While it is suggested that the 
invention may be used for medical applications such as the 
determination of sugar in diabetics, specific details on how 
this might be accurately carried out are not provided. 
U.S. Pat. No. 5,710,30 to Essenpreis suggests a method 
for measuring the concentration of glucose in a biological 
sample such as the eye (see FIG. 4 therein) with interfero- 
metric measurement procedures. 
U.S. Pat. No. 5,666,956 to Buchert et al. suggests that an 
instrument for the non-invasive measurement of a body 
analyte can be based on naturally emitted infrared radiation. 
In spite of the foregoing efforts, a commercially viable, 
non-invasive, blood glucose monitor based on a non- 
invasive analysis of the aqueous humor of the eye has not yet 
been developed. Difficulties in developing such a device 
include correlation of aqueous humor glucose levels to 
blood glucose levels, the difficulty of obtaining accurate 
measurements, and the need to minimize damaging effects to 
the eye caused by excessive exposure to light in an instru- 
ment that will be used by subjects on a repeated basis. 
Accordingly, there is a continued need for new methods for 
the non-invasive analysis of blood glucose levels. 
SUMMARY OF THE INVENTION 
A first aspect of the present invention is a non-invasive 
method for determining blood level of an analyte of interst, 
such as glucose. The method comprises: 
generating an excitation laser beam (e.g., at a wavelength 
of 700 to 900 nanometers); 
focusing the excitation laser beam into the anterior cham- 
ber of an eye of the subject so that aqueous humor in 
the anterior chamber is illuminated; 
detecting (preferably confocally detecting) a Raman spec- 
trum from the illuminated aqueous humor; and then 
determining the blood glucose level (or the level of 
another analyte of interest) for the subject from the 
Raman spectrum. 
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Preferably, the detecting step is followed by the step of 
subtracting a confounding fluorescence spectrum from the 
Raman spectrum to produce a difference spectrum; and 
determining the blood level of the analyte of interest for the 
subject from that difference spectrum, preferably using 
linear or nonlinear multivariate analysis such as partial least 
squares or artificial neural network algorithms. 
A second aspect of the present invention is an apparatus 
for the non-invasive determination of the blood level of an 
analyte of interest such as glucose in a subject. 
The apparatus comprises: 
a laser for generating an excitation laser beam (e.g., at a 
wavelength of from 700 to 900 nanometers); 
an optical system (e.g., a confocal optical system) opera- 
tively associated with said laser for focusing the exci- 
tation laser beam into the anterior chamber of an eye of 
the subject so that aqueous humor in the anterior 
chamber is illuminated; 
a detector operatively associated with the optical system 
and configured to detect a Raman spectrum from the 
illuminated aqueous humor; 
preferably a subtraction system, hardware and/or software 
processor or other suitable means for subtracting a 
fluorescence spectrum for said aqueous humor from 
said Raman spectrum to produce a difference spectrum; 
and 
a processor for determining the blood level of the analyte 
of interest for said subject from the Raman spectrum 
(or preferably the difference spectrum). 
Numerous additional features may be incorporated into the 
apparatus. The apparatus may include an visual display 
screen for visually displaying the results of the test to the 
subject through the same aperture as which the test is 
conducted. It may include a visual fixation device, also 
visible through the test aperture, which controls movement 
of the eye and simultaneously insures that focusing of the 
laser beam is properly directed into the anterior chamber of 
the eye. The processor may contain an empirical model of 
actual testing experience to determine the blood level of the 
analyte of interest. The apparatus may employ a tunable 
laser, a plurality of fixed wavelength lasers, or other means 
for sliding the Raman spectrum passed a plurality of differ- 
ent wavelength detectors to obviate the need for a full 
grating based Raman spectrometer. A communication line 
connected to the processor for transmitting the blood level of 
the analyte of interest to a remote location. 
Still other features that can be included in the methods and 
apparatus described above set forth below. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 illustrates that the broad fluorescence spectrum of 
aqueous humor can obscure the underlying peaks of interest 
in the Raman spectrum. Unlike the fluorescence spectrum, 
the Raman spectra will shift with a change in the excitation 
wavelength. The raw spectrum of rabbit aqueous humor is 
shown taken at 2 slightly different wavelengths (top). The 
difference spectrum (bottom) achieved by subtracting 1 raw 
spectrum from the other reveals a resultant bipolar Raman 
signature. Linear and nonlinear multivariate analysis can 
then be applied. 
FIG. 2. The glucose concentration in aqueous humor from 
16 rabbits was estimated with Raman spectroscopy and 
compared to the actual glucose concentration measured with 
a commercial glucometer. The graph shows the Raman 
predicted glucose concentration after subtracting 
fluorescence, and applying a linear partial least square 
4 
algorithm followed by nonlinear backpropagation with an 
artificial neural network. This resulted in a high degree of 
correlation (r2=0.98) of predicted with actual glucose con- 
centration. Applying the partial least squares algorithm 
s alone resulted in lesser correlation (r2=0.90). 
FIG. 3. Blood glucose steadily rises at variable rates in 
rabbits after administration of xylazine anesthesia. On ani- 
mal (rabbit D, filled diamonds) had little change in blood 
glucose for unknown reasons. 
FIG. 4. Best-fit second-order polynomial curves demon- 
strate the relationship between aqueous humor glucose and 
plasma glucose while plasma glucose is rising in 9 animals. 
Aqueous glucose measurements from the first paracentesis 
of an eye correlate well with simultaneous plasma glucose 
(dark curve). When plasma glucose exceeds 200 mg/dL the 
relationship is nearly linear (dashed line). Aqueous humor 
glucose exceeds plasma glucose when plasma glucose is less 
than 200 mgidL. The relationship of aqueous humor glucose 
with plasma glucose is different when the aqueous humor 
2o sample is obtained as a second paracentesis (light curve) 
suggesting that the initial paracentesis disrupts normal glu- 
cose homeostasis. 
FIG. 5 schematically illustrates a first embodiment of an 
apparatus of the invention. 
FIG. 6 schematically illustrates a second embodiment of 
an apparatus of the invention. 
FIG. 7a  schematically illustrates the method of sliding 
Raman spectra features through a particular detector win- 
FIG. 7b schematically illustrates an apparatus of the 
FIG. 8 illustrates a visual fixation display that can be 
FIG. 9 illustrates a visible readout display that can be 
lo 
25 
30 dow by changing excitation frequency. 
invention that utilizes the method illustrated in FIG. 7a. 
utilized in an apparatus of the invention. 
utilized in an apparatus of the invention. 
35 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS 
40 The term “glucose” as used herein preferably refers to 
D-glucose. 
The term “subject” as used herein refers to both human 
subjects and animal subjects such as dogs, cats, and rabbits. 
45 Animal subjects may be used in the present invention for 
veterinary purposes. Human subjects are preferred. 
The term “processor” as used herein refers to a hardware 
device, a software or program-implemented device running 
on a general-purpose computer, or combinations of such 
hardware and software devices. 
The present invention is primarily concerned with the 
determination of blood glucose levels, and is so explained 
herein. However, the blood concentration of other Raman- 
active molecules or analytes such as lactate, urea, ascorbate, 
5s drugs, steroids, and alcohol (particularly ethanol) may also 
be determined by these techniques. 
The step of generating an excitation laser beam pulse can 
be carried out with any suitable laser beam source. The 
power of the excitation laser beam pulse should be suffi- 
60 ciently low to avoid tissue toxicity, but sufficiently high to 
provide a measurable Raman signal from the aqueous 
humor. In general, the laser beam pulse will be at a wave- 
length of from 700 to 900 nanometers, and more preferably 
will be at a wavelength of 780 to 860 nanometers to reduce 
65 fluorescence, increase tissue penetration, and reduce photo- 
toxicity to the eye. The duration of the pulse will typically 
be from 1 to 2 seconds to 30 seconds or 60 seconds (i.e., 
US 6,181,957 B3 
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one-half minute to one minute). The total energy of the laser 
pulse will typically be 200-500 millijoules with instanta- 
neous power not exceeding 30 or 50 milliwatts. The optical 
components of the apparatus used to carry out the method 
are preferably configured so that energy on the retina of the 
eye (as well as other areas susceptible to tissue toxicity, such 
as the lens and cornea) from the excitation laser beam pulse 
is not greater than 3000 milliwatts per square centimeter, and 
more preferably not greater than 2000, 1000 or even 500 
milliwatts per square centimeter. 
Any source laser that provides the desired frequency 
output may be employed in carrying out the invention. A 
distributed feedback laser can be used to reduce instrument 
6 
analyte of interest), or both. Typically, the training set would 
require at least 20, 25 or 30 Raman spectra samples (and 
samples of the corresponding blood levels of the analyte of 
interest) with substantial inter-sample variability in the 
5 levels of the major Raman scattering metabolites (e.g., 
glucose, ascorbate, lactate, urea, and any drugs or exogenous 
compounds present). The concentration of the analyte of 
interest (in either the blood or aqueous humor) should vary 
by at least a factor of 2 ,5 ,10  or 20 or more from the sample 
with the lowest concentration to the sample with the highest 
concentration. This may require development of the model 
using subjects with multiple different diseases (e.g., renal 
failure, diabetes, seizures, mitochondrial myopathies, sickle 
size. Tunable or multiple fixed frequency lasers can be cell disease, heart failure, blood clots, etc.). For human 
combined with bandpass filters (Puppels et al., Applied 15 applications, the model may even be determined with spec- 
Spectroscopy 47, 1256-67 (1993)) that select for Raman tra samples obtained from animals, particularly primates. 
scattering at wavelengths that provide optimum information The aqueous humor sample may be a natural sample, 
for multivariate analysis (this reduces the cost and size of the (human or animal), or may be a man-made or surrogate 
instrument compared to the use of holographic filters or aqueous humor sample created to mimic natural samples, 
gratings). 2o where the blood level is calculated from a priori knowledge 
Any suitable detector can be used to detect a Raman of the relationship between blood levels and aqueous humor 
spectrum from illuminated aqueous humor. A CCD detector levels for the anal@ of interest. 
or CCD camera is preferred. The CCD detector preferably For example, where the analyte of interest is glucose, the 
has high quantum efficiency in the near infrared range. The training set of samples for the empirical model should 
high quantum efficiency may be achieved by any suitable 25 comprise at least 20, 25 or 30 aqueous humor spectra 
means, such as employing a backthinned detector, but one samples, with the corresponding blood glucose levels, where 
sufficiently thick to reduce etalon effect. the principal Raman active compounds in the aqueous 
The fluorescence spectrum for the aqueous humor can be humor samples (glucose, ascorbate, lactate, urea, and pref- 
subtracted from the Raman spectrum by stimulating the erably any exogenous compounds such as drugs) vary 
aqueous humor with a second excitation laser light pulse at 30 substantially non-colinearly among the samples, with either 
a wavelength slightly different from that of the first pulse the blood or aqueous humor glucose concentration ranging 
(e.g., up to two nanometers from the first pulse), and then from 0 or 50 mg/dL to 800 or 1,000 mg/dL, and with there 
subtracting one spectrum from the other in a processor in being at least 100,200,300 or 400 mddL difference in said 
accordance with conventional techniques. Such techniques concentration between the sample with the lowest concen- 
are known. See, e.g., Funfschilling and Williams, Applied 35 tration and the sample with the highest concentration. 
Spectroscopy 30, 443 (1976); Baraga et al., Applied Spec- A schematic diagram of the general apparatus is depicted 
troscopy 46, 187 (1992); Wicksted et al., Applied Spectros- in FIG. 5. A tunable, narrow-band laser beam from laser 10 
copy 49, 987 (1995)). In the alternative, the fluorescence is focused into the anterior chamber 11 of the eye 12 through 
spectrum can be subtracted out through the use of software an objective or ocular lens 13 via lens 15 and filter 16, beam 
or other processing techniques. Thus the term “subtraction” 40 splitter 17, and filter 20. A non-fluorescing objective lens is 
as used herein is intended to include techniques such as chosen with suitable numerical aperture (e.g. 0.2-0.5) such 
filtering. While not essential, other potentially interfering that Raman scattering from the aqueous humor is maximized 
spectra or signals such as Raman scattering from the lens, while scattering from adjacent structures (e.g. lens, cornea, 
iris, or cornea, can also be filtered or subtracted through a and iris) is minimized. The objective lens should have 
hardware and/or software processor. Water is typically not 45 adequate working distance to permit focusing of the laser 
an issue for Raman spectroscopy, but a water spectrum can into the middle of the anterior chamber of the eye without 
be subtracted if desired. touching the cornea. An integrated fixation target projected 
The blood glucose level for the subject is then determined from display screen 25 is projected via lens 26 through the 
from the difference spectrum by an empirically based model, same objective lens as the laser, but is focused on the retina 
formula, or matrix of actual subject or sample testing in a so of the eye. Focusing this fixation target on the retina 
hardware and/or software processor. The model can be simultaneously controls direction and focusing of the laser 
obtained through linear (e.g., partial least squares) or non- light in the anterior chamber. 
linear (e.g., artificial neural networks) multivariate analysis. The light collected by the objective lens is directed 
It is important that the training set of Raman spectra used for through holographic notch filters 20, 21 to remove the 
the multivariate analysis include samples from aqueous ss Raleigh scattered light. The Raman scattered light passes 
humor with a broad range of concentrations of the Raman through these filters with minimal attenuation and is focused 
scattering metabolites. The principal Raman-scattering through a confocal pinhole aperture 22 by lenses 23,24. The 
metabolites (or “Raman active compounds”) (glucose, pinhole and the focal point in the anterior chamber of the eye 
lactate, urea, ascorbate, and any exogeneous compounds or are confocal such that light from adjacent structures in the 
drugs present) preferably should not vary co-linearly with 60 eye is filtered at this aperture. The pinhole also serves as the 
one another among the samples in the training set. The entrance aperture to the spectrometer. The spectrometer 
model can be produced with spectra samples obtained from shown is an imaging spectrograph with a grating 30, lens 31 
one or more prior subjects, can be produced with spectra and a CCD detector array 32. A computer 35 controls the 
samples obtained from the subject from whom the current laser 10, the fixation target and readout display 25, and 
blood level of the analyte of interest is being determined (in 65 receives data from the CCD detector 32. The architecture of 
which case that subject would be required to provide a blood the spectrometer is merely an example of one that is suitable 
sample for determination of the blood concentration of the for this application. Many types of spectrographs could be 
US 6,181,957 B1 
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utilized including Fourier transform spectrographs, spectro- could instead use a set of narrowly tunable lasers each with 
graphs using liquid crystal tunable filters or other tunable a different center wavelength as the laser means in conjunc- 
elements. Information can be transmitted to a remote source tion with a series of bandpass filteddetectors for this pur- 
such as a computer, database, remote physician or the like pose. 
via modem or other connection through a suitable commu- 5 Advantageously, the systems described herein may be 
nication line 36 via the internet, world wide web, etc. configured so that optical components need not and do not 
The CCD detector in the spectrograph is of a red-shifted, contact the cornea of the eye during use, which many 
back-thinned, thick epitaxial design such that its sensitivity patients find objectionable (e.g., by providing a suitable 
is optimal in the 700-1100 nanometer spectral region. Other monocular eye cup for contacting the orbit around the eye). 
types of very sensitive detectors may be suitable as well. The apparatus of the invention can be implemented as a 
As noted above, a digital computer processes the output spectrometer base unit attached by a fiberoptic cable to an 
of the CCD detector and controls the frequency and the ocular probe, or as a single integrated unit including 
power of the laser source. The computer switches the foreoptics, spectrometer, detector, computer and display. 
frequency of the laser to permit subtraction of fluorescence noted above, a visual fixation target such as a mirror, 
as described previously. The computer also provides infor- LED or the like can be built into the optical apparatus to 
patient reads the results of the analysis on this display. chamber and maintain stability of the eye. In the embodi- 
Fibers 40, 41 may be used to deliver the laser beam and ment of FIGS. 5-7, a display screen such as a liquid crystal 
collect the Raman scattered light as depicted in FIG. 6. (like 2o display is employed, As shown in FIG. 8, a blinking fixation 
components in FIGS. 5 and 6 are assigned the Same target in the form of an hourglass 70 can be displayed, 
numbers). In this embodiment the confocal aperture is a focused on the retina, during acquisition of the spectra by the 
circular aperture 42 placed on the end of a multimode fiber. apparatus, This will help optimize the Raman signal from 
As with the pinhole aperture in FIG. 5,  the end of said fiber the aqueous humor and reduce light exposure to other 
is placed SO that it is confocal with the objective lens’focal structures of the eye, The fixation target is active and 
point in the anterior chamber of the eye. Asingle mode fiber 25 displayed during the time that the laser beam is active and 
is used to deliver the laser beam into the anterior chamber. illuminating the subject’s aqueous humor, As shown in FIG. 
This single mode fiber insures a diffraction limited spot size 9, a visible indication of the results of the test in the form of 
at the focal point of the objective. alphanumeric indicia 71 (or other suitable form, such as a 
Such a fiber delivery and collection system depicted in 3o graphical display) can be displayed on the same screen 
FIG. 6 can be connected to an alternative detection system immediately after the acquisition step. The indicia of FIG. 9 
shown in FIG. 7u-b. This alternative detection system will provide a readout for all of the principal Raman-active 
allow for subtraction of the fluorescence spectrum and as compounds of the aqueous humor, but only one need be so 
well as selected sampling of the frequencies most important displayed. 
for calculation of glucose concentration. Such an alternative 35 The instrument of the invention can be operatively asso- 
detection system would decrease the size and cost of the ciated with a patient’s insulin pump (for ~ - ~ l ~ ~ ~ ~ ~ )  or to a 
instrument. dialysis machine (for urea) by electrical or fiber optic lines, 
The system depicted in FIG. 7 uses one or more fixed radio frequency transmitters and receivers or the like to 
frequency or tunable lasers to illuminate the aqueous humor provide information on the appropriate analyte that can then 
of the eye using the optical delivery system shown in FIG. 40 be used to control that apparatus and increase or decrease the 
6. output of the insulin pump in response to blood glucose 
FIG. 7u illustrates that each spectral feature 50u, 50b, 50c levels, or to regulate the dialysis machine. 
of the Raman scattered light is related to the excitation In telemedicine applications, the instrument of the inven- 
wavelength by a fixed offset, usually expressed in wave- tion can be conveniently operatively associated with a 
numbers. Changing the excitation wavelength causes the 4s remote read-out terminal through a computer, modem, inter- 
Raman spectra to shift in wavelength, as depicted by the net connection or other communication line with any any 
different feature captured in detector range D, 51 based on suitable means (such as an electrical or fiber optic lines, 
Raman spectra 52 for excitation frequency Lhl as compared radio frequency transmitters and receivers, etc.) to provide 
to Raman spectra 53 for excitation frequency Lh2. information on the blood analyte to a remote physician or 
An apparatus that takes advantage of the foregoing is SO medical provider (e.g., through the internet or world wide 
schematically illustrated in FIG. 7b. Like components to web). 
FIGS. 5 and 6 are assigned like numbers. Laser Drivers and The present invention is explained in greater detail in the 
or tuning electronics 60 are operatively associated with a following nonlimiting ~ ~ ~ ~ ~ l ~ ~ ,  in which “,c’ 
tunable laser or a plurality of fixed wavelength lasers 61,62, microliters; “d c’ deciliters, ‘‘mw’ milliwatts, 
63. Aseries of one or more bandpass filteddetector elements ss “nm” 
65,66, 67 operatively associated with amplifiers and analog joules, ((cm2>> square centimeters, and temperatures 
to digital converter 68 is used to sample the spectrum of the are given in degrees Centigrade, 
collected light. The center wavelength and bandwidth of 
each filter is chosen to correspond with a different Raman EXAMPLE 1 
spectral peak of aqueous humor important for quantification 60 
Measurement of aqueous humor glucose in vitro of glucose. If this laser is tunable over a nanometer or so, 
with Raman Spectroscopy subtraction of the fluorescent components of the acquired 
spectrum would also be possible as discussed earlier. Using Aqueous humor was obtained from sixteen New Zealand 
a laser with a wider tuning range would allow the Raman white rabbits within one minute of sacrifice by other inves- 
shifted spectra to be scanned or slid across a smaller number 65 tigators. These animals had experienced experimental myo- 
of bandpass filteddetectors. Since semiconductor lasers with cardial infarction 48 hours prior to euthanasia. They were 
extremely wide tuning ranges are not readily available, one sacrificed by rapid exsanguination under ketamine and xyla- 
10 
mation to a digital display imaged onto the retina. The facilitate focusing of the excitation light into the anterior 
nanometers, “K,” kilograms, “J” 
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zine anesthesia. Aqueous humor samples were kept frozen 
until glucose levels could be measured and Raman spec- 
troscopy performed. Glucose concentration was measured 
with a commercial glucometer (Glucometer Elite, Bayer, 
Elkhart, Ind., USA) and confirmed against concentration 
standards. Each measurement was repeated, and the average 
measurement was considered actual glucose concentration. 
Samples were placed in conical quartz cuvettes designed 
to hold a volume of 80 pL and permit direct optical access 
to the solution by the spectrometer without traversing glass 
walls or coverslips. 
Raman spectroscopy was performed with a fi1.8 holo- 
graphic imaging spectrograph (Kaiser Optical Systems, Ann 
Arbor, Mich., USA) attached to an Olympus BX60 micro- 
scope with lox  objective. Data were collected using a 
Princeton Instruments (Trenton, N.J., USA) camera with a 
1024x256 CCD array (EEV, United Kingdom) cooled to 
-80” C. with liquid nitrogen. Illumination of the sample 
through the microscope objective was achieved with a 
Ti:Sapphire laser (Spectra Physics 3900S, Mountain View, 
Calif., USA) pumped by an argon laser (Spectra Physics 
2010E). Spectrographic data was integrated while the 
sample was illuminated at a wavelength of 785.0 nm (30 
mW) for 10 seconds. This was then repeated at a wavelength 
of 787.2 nm. 
The integrated spectra at the two slightly different wave- 
lengths were then subtracted from one another. This effec- 
tively eliminates the broadband fluorescence, which does 
not shift relative to the excitation wavelength. It leaves the 
Raman-shifted spectra appearing as a bipolar pattern. (FIG. 
Multivariate analysis of the spectra was accomplished 
using Holograms (Princeton Instruments, Trenton, N.J.) and 
Grams (Galactic Industries, Salem, N. H., USA) software 
packages. Thirty-two aqueous humor samples (from sixteen 
rabbits) were evaluated using a “round robin” approach to 
iteratively group all but one of the samples into a training 
set. Hence, the system trains on all but one of the samples, 
estimates the glucose level in that sample, then rotates the 
test sample into the training set. This cycle is repeated until 
all samples have served as an unknown test sample. 
We subsequently employed a backpropagation neural 
network (D. Rumelhart et al., Nature 323, 533 (1986)) to 
determine if a nonlinear regression method would better 
predict the glucose concentration from the Raman spectra of 
aqueous humor. Such a model may compensate for as yet 
unknown interactions between analytes in aqueous humor. 
We employed a two-layer backpropagation neural network 
(Neuralware, Inc., Pittsburgh, Pa., USA) using a sigmoidal 
function as the nonlinear element. Factors derived from the 
partial least squares algorithm served as the inputs to the 
neural network. Raw spectral data could have been used but 
would have required a prohibitively large training set. As in 
the linear regression preformed earlier, round robin training 
and testing was utilized. During training, the neural net- 
work’s weights were adjusted to minimize the total squared 
error between the actual glucose concentration and the 
predicted glucose concentrations. Each sample was tested 
using a neural network trained on the remaining 31 samples. 
EXAMPLE 2 
Correlation of Aqueous Humor Glucose with 
Rising Blood Glucose 
Nine female New Zealand white rabbits were used for this 
part of the study. They were anesthetized with ketamine (50 
1) 
10 
mg/kg) and xylazine (7.5 m a g )  given as a single intra- 
muscular injection. Xylazine blocks release of insulin from 
the pancreas and causes blood glucose to rise (K. Chalabi et 
al., Ophthalmic Res. 19, 289 (1987); J. Arnbjerg et al., 
s Ophthalmic Res. 22, 265 (1990)). 
Blood samples were taken from the central ear arteries at 
various times following the injection of anesthetic once the 
animals were adequately anesthetized. Whole blood was 
immediately measured for glucose concentration with a 
10 commercial glucometer (Glucometer Elite, Bayer). In most 
instances two measurements were made. The average mea- 
surements are reported. If the measurements differed by 
more than 20%, a third measurement was made. If one 
measurement differed by more than 20% from the mean, it 
15 was discarded. In instances when blood glucose concentra- 
tion appeared stable, occasionally only one measurement 
was made. 
At various times after induction of anesthesia, samples of 
aqueous humor were taken. This was done by paracentesis 
’O with a 25-gauge needle through clear cornea near the limbus 
after administration of proparacaine eye drops. Aqueous 
humor glucose concentration was measured with the glu- 
cometer in a manner similar to the blood. 
In rabbits, there is massive breakdown of the blood- ’’ aqueous barrier after a single paracentesis of the anterior 
chamber of the eye (W. Unger et al., Exp. Eye Res. 20,255 
(1975)). The aqueous humor becomes too viscous for repeat 
paracentesis for at least 30 minutes. Consequently, our 
results are reported for the first paracentesis of an eye. In a 
30 few instances, however, a second paracentesis was made an 
hour later to assess how the breakdown of the blood-aqueous 
barrier may have affected the correlation of aqueous glucose 
with plasma glucose. 
Average blood glucose concentrations for each animal 
were plotted against time after anesthetic injection. Since it 
was impossible to obtain blood samples simultaneous with 
aqueous humor samples, a best-fit second-order polynomial 
was calculated for each animal. This was used to calculate 
4o the blood glucose concentration at the time that the aqueous 
humor sample was taken. Aqueous humor glucose concen- 
tration was then plotted against the calculated simultaneous 
blood glucose concentration for all animals. DeltaGraph 
software (Delta Point, Inc., Monterey, Calif., USA) was used 
EXAMPLE 3 
Results for Measurement of Aqueous Humor 
Glucose In Vitro with Raman Spectroscopy 
The raw spectra of rabbit aqueous humor show broad 
fluorescence peaks that obscure the underlying Raman sig- 
nature. (FIG. 1) When the spectra from the two slightly 
different wavelengths are subtracted, one from the other, the 
Raman shifted spectra become apparent as bipolar peaks. 
Actual aqueous humor glucose concentration, measured 
by the glucometer, ranged from 37 to 323 mg/dL in the 
thirty-two samples. Multivariate analysis of the raw spectra 
from these samples with the partial least squares algorithm 
revealed fair correlation (r2=0.76) between the predicted 
60 aqueous humor glucose concentration and the actual con- 
centration. Multivariate analysis of the subtracted spectra 
from these samples with the partial least squares algorithm 
resulted in improved correlation (r2=0.90) between the pre- 
dicted aqueous humor glucose concentration and the actual 
65 concentration. When backpropagation with an artificial neu- 
ral network is further applied to the data, correlation is 
excellent (r2=0.98). (FIG. 2). 
35 
45 for all statistical calculations. 
50 
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EXAMPLE 4 
Results for Correlation of Aqueous Humor Glucose 
with Rising Blood Glucose 
The rate of rise of blood glucose after xylazine injection 
is highly variable from animal to animal. (FIG. 3) In fact, in 
one rabbit there was little change in the blood glucose 
concentration over time. 
If only samples taken in the first fifteen minutes after 
anesthetic injection are considered, aqueous humor glucose 
concentration is higher than blood glucose concentration 
(207228 mg/dL for aqueous humor; 135227 mg/dL for 
blood). When calculated blood glucose rises above 200 
mg/dL, simultaneous aqueous humor glucose parallels blood 
glucose nearly linearly [aqueous humor glucose=1.18 (blood 
glucose)-72.7; r2=0.88]. (FIG. 4) 
The number of aqueous humor samples from second 
paracenteses was insufficient to draw conclusions about their 
significance. They did not appear, however, to correlate well 
with aqueous humor glucose levels from initial paracente- 
ses. (FIG. 4) 
These data indicate that the baseline ratio of aqueous 
humor glucose to blood glucose in rabbits is approximately 
1.5. (It may actually be higher than this as a true baseline 
was not obtained, and the blood glucose levels were likely 
elevated by the time the first samples were obtained, even in 
the first 15 minutes after injection.) This is much higher than 
in humans and higher than in previous reports on rabbits. All 
previous reports on rabbits, however, were prior to recog- 
nition of the hyperglycemic effect of xylazine anesthesia, yet 
many of them used xylazine anesthesia. In addition, most 
previous reports assumed that the rabbits were at steady- 
state euglycemia, without actually confirming that this was 
the case. These facts may account for some of the highly 
variable results in previous reports. 
These data also demonstrate that aqueous humor glucose 
in the rabbit responds almost immediately once blood glu- 
cose exceeds 200 mgidL. The relationship of aqueous humor 
glucose to blood glucose is nearly linear while blood glucose 
is rising above 200 mg/dL. Below that level, aqueous humor 
glucose appears stable. What happens to aqueous humor 
glucose when blood glucose is clamped at a hyperglycemic 
level, or when blood glucose concentration drops has yet to 
be determined. Nonetheless, equilibration of aqueous humor 
glucose with blood glucose probably occurs within minutes 
in rabbits. If rapid equilibration of aqueous humor glucose 
also occurs in humans, it could serve as an excellent 
substrate for non-invasive glucose monitoring. 
Previous investigators have found no breakdown in the 
blood-aqueous barrier of albino rabbits exposed to infrared 
radiation with energy densities up to 106 J/cm (D. Reddy, 
supra; G. Peyman et al., Exp. Eye Res. 42, 249 (1986); T. 
Kurnik et al., Znv. Ophthalmol. vls. Sci. 30, 717 (1989)). 
Infrared energy densities as low as 44 J/cm2 may be suffi- 
cient to breakdown the blood-aqueous barrier in pigmented 
rabbits, however. This is still substantially higher than the 
energy density that would need be applied with the Raman 
technique disclosed herein. 
EXAMPLE 5 
Measurement of Integrity of Blood-Aqueous and 
Blood-Brain Barriers 
The blood-brain and blood-aqueous barriers block pas- 
sage of large molecules into the cerebrospinal fluid or 















disruption of both the blood-aqueous barrier and the blood- 
brain barrier. In the case of such drugs or disease processes, 
disruption of the blood-brain barrier can be inferred from 
breakdown of the blood-aqueous barrier. Breakdown of the 
blood-aqueous barrier can be measured by measuring the 
protein content of the aqueous humor or by measuring the 
concentration of other substances (e.g., drugs) within the 
aqueous humor. Such substances may be quantifiable by 
Raman spectroscopy and the protein can be calculated from 
the fluorescence spectrum since the fluorescence spectrum is 
largely generated by protein. Consequently, the device dis- 
close herein for measuring glucose and other Raman scat- 
tering metabolites in the eye can be used for measuring the 
integrity of the blood-aqueous and blood-brain barriers. 
Raman scattering molecules of different sizes that do not 
normally cross the blood-aqueous or blood-brain barrier 
could be administered to a patient intravenously. The pres- 
ence of these molecules is then quantified by Raman spec- 
troscopy of the anterior chamber of the eye. This can be used 
to determine the size of molecules which pass through the 
blood aqueous barrier. The amount of fluorescence that is 
subtracted to reveal the Raman spectra of these substances, 
with the device disclosed herein would reflect the passage of 
natural proteins through the blood-aqueous and blood brain 
barriers. 
Therapeutic drugs can also be measured to determine their 
effectiveness in crossing the blood-aqueous or blood-brain 
barrier. 
The foregoing is illustrative of the present invention, and 
is not to be construed as limiting thereof. The invention is 
defined by the following claims, with equivalents of the 
claims to be included therein. 
We claim: 
1. A non-invasive method for determining blood glucose 
generating an excitation laser beam at a wavelength of 
from 700 to 900 nanometers; 
focusing said excitation laser beam into the anterior 
chamber of an eye of said subject so that aqueous 
humor in said anterior chamber is illuminated; 
detecting a Raman spectrum from said illuminated aque- 
ous humor; 
subtracting a fluorescence spectrum for said aqueous 
humor from said Raman spectrum to produce a differ- 
ence spectrum; and then 
determining the blood glucose level for said subject from 
said difference spectrum. 
2. Amethod according to claim 1, wherein said laser beam 
pulse has a duration not greater than thirty seconds. 
3. Amethod according to claim 1, wherein said laser beam 
pulse has an instantaneous power not greater than 30 mil- 
liwatts. 
4. A method according to claim 1, wherein said focusing 
step is carried out so that energy on the retina of said eye 
from said excitation laser beam pulse is not greater than 
3000 milliwatts per square centimeter. 
5 .  A method according to claim 1, further comprising the 
step of subtracting the spectrum of adjacent tissues from said 
Raman spectrum. 
6. A method according to claim 1, wherein said subject is 
a human subject. 
7. Amethod according to claim 1, wherein said determin- 
ing step is carried out with an empirical model of actual 
testing experience. 
8. A method according to claim 7, wherein said empirical 
model is generated by multivariate analysis. 
levels in a subject, comprising: 
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9. A method according to claim 8, wherein said multi- 
variate analysis is a partial least squares analysis. 
10. A method according to claim 7, wherein: 
said empirical model is produced with a training set 
comprising at least 20 aqueous humor samples, a 
Raman spectra corresponding to each of said samples, 
and a blood glucose level corresponding to each of said 
samples; 
with the concentration of glucose in either the aqueous 
humor samples or corresponding blood samples vary- 
ing by at least 200 mgidL from the sample with the 
lowest concentration to the sample with the highest 
concentration. 
11. A method according to claim 10, wherein the concen- 
tration of the principle Raman-active compounds in said 
samples vary substantially non-colinearly among said 
samples. 
12. An apparatus for the non-invasive determination of a 
blood level of an analyte of interest in a subject, comprising: 
a laser for generating an excitation laser beam; 
an optical system operatively associated with said laser 
for directing said excitation laser beam into the anterior 
chamber of an eye of said subject so that aqueous 
humor in said anterior chamber is sufficiently illumi- 
nated to detect Raman scattered light; 
a detector operatively associated with said optical system 
and configured to detect a Raman spectrum from said 
aqueous humor; 
means for subtracting a fluorescence spectrum for said 
aqueous humor from said Raman spectrum to produce 
a difference spectrum; and 
a processor for determining the blood level of said analyte 
of interest for said subject from said difference spec- 
trum; and 
a display target projected through said optical system that 
visually displays said blood level of said analyte of 
interest. 
13. An apparatus according to claim 12, further compris- 
ing a fixation target operatively associated with and pro- 
jected through said optical system to assure proper direction 
and focusing of the laser beam into the anterior chamber of 
the eye. 
14. An apparatus according to claim 12, wherein said 
optical system is a confocal optical system. 
15. An apparatus according to claim 12, wherein said laser 
beam has a wavelength of from 700 to 900 nanometers. 
16. An apparatus for the non-invasive determination of a 
blood level of an analyte of interest in a subject, comprising: 
a laser for generating an excitation laser beam; 
an optical system operatively associated with said laser 
for directing said excitation laser beam into the anterior 
chamber of an eye of said subject so that aqueous 
humor in said anterior chamber is illuminated suffi- 
ciently to detect Raman scattered light; 
a detector operatively associated with said optical system 
and configured to detect a Raman spectrum from said 
aqueous humor; 
means for subtracting a fluorescence spectrum for said 
aqueous humor from said Raman spectrum to produce 
a difference spectrum; 
a processor for determining the blood level of said analyte 
of interest for said subject from said difference 
spectrum, said processor including an empirical model 
of actual testing experience. 
17. An apparatus according to claim 16, wherein said 
empirical model is generated by multivariate analysis. 
18. An apparatus according to claim 17, wherein said 
multivariate analysis is a partial least squares analysis. 
19. An apparatus according to claim 16, wherein: 
said empirical model is produced with a training set 
comprising at least 20 aqueous humor samples, a 
Raman spectra corresponding to each of said samples, 
and a blood level of said analyte of interest correspond- 
ing to each of said samples; 
with the concentration of said analyte of interest in either 
the aqueous humor samples or corresponding blood 
samples varying by at least a factor of 5 from the 
sample with the lowest concentration to the sample 
20. An apparatus according to claim 16, further compris- 
ing a communication line connected to said processor for 
transmitting said blood level of said analyte of interest to a 
remote location. 
21. An apparatus according to claim 16, wherein said 
optical system is a confocal optical system. 
22. An apparatus according to claim 16, wherein said laser 
beam has a wavelength of from 700 to 900 nanometers. 
23. An apparatus according to claim 16, wherein said 
24. An apparatus for the non-invasive determination of a 
blood level of an analyte of interest in a subject, comprising: 
laser means for generating a plurality of excitation laser 
beams at a plurality of different wavelengths; 
an optical system operatively associated with said laser 
means and configured to direct said excitation laser 
beams into the anterior chamber of an eye of said 
subject so that aqueous humor in said anterior chamber 
is sufficiently illuminated to detect Raman scattered 
light; 
detector means operatively associated with said optical 
system and configured to detect a Raman spectrum 
from said aqueous humor at a plurality of detector 
control means operatively associated with said laser 
means for sliding said Raman spectrum through said 
plurality of detector wavelengths; 
means for subtracting a fluorescence spectrum for said 
aqueous humor from said Raman spectrum to produce 
a difference spectrum; and 
a processor for determining the blood level of said analyte 
of interest for said subject from said difference spec- 
trum. 
25. An apparatus according to claim 24, wherein said laser 
26. An apparatus according to claim 24, wherein said laser 




20 with the highest concentration. 
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means comprises a tunable laser. 
means comprises a plurality of fixed frequency lasers. 
6o optical system is a confocal optical system. 
* * * * *  
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